← Leaderboards
Kurt Jarnagin
Synbal, Inc.
$4,100,259
Attributed
$4,100,259
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,100,259 · 2
By mechanism
N44$2,000,000 · 1
R44$1,800,259 · 1
N01$300,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Communities”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$274,807,335
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Joel A Lipkin · Four Points Technology, Llc$178,737,225
- John E West · University Of Texas At Austin$130,233,001
- Leonard Freedman · Leidos Biomedical Research, Inc.$98,171,500
Research focus
CommunitiesSalesPharmacologic SubstanceGrantAnimalsGenesGeneticKnock-InSmall Business Innovation Research GrantAntiviral TherapyCellsAntibody ResponseCellular ImmunityCellular Membrane2019-NcovExtracellularAce2Covid-19 SusceptibilityCovid-19AntibodiesBusinessesDisease ModelDrug DevelopmentEmbryo
Grant awards (5)
Triple humanized ACE2-TMPRSS-FcGRT mouse models for COVID research in the C57BU6 and BALBIc backgrounds.$566,896
R44 · FY2023 · AI · contact PI
Triple humanized ACE2-TMPRSS-FcGRT mouse models for COVID research in the C57BU6 and BALBIc backgrounds.$1,000,000
R44 · FY2022 · AI · contact PI
Triple humanized ACE2-TMPRSS-FcGRT mouse models for COVID research in the C57BU6 and BALBIc backgrounds.$233,363
R44 · FY2021 · AI · contact PI
IGF::OT::IGF Topic 372 Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics- Moonshot$2,000,000
N44 · FY2019 · CA · contact PI
IGF::OT::IGF Topic 372 Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics- Moonshot$300,000
N01 · FY2018 · CA · contact PI